Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

被引：14

作者：

Lu, X. -L. ^{[1
]}

Cao, X. ^{[2
]}

Liu, X. -Y. ^{[1
]}

Jiao, B. -H. ^{[1
]}

机构：

[1] Second Mil Med Univ, Dept Biochem & Mol Biol, Fac Basic Med Sci, Shanghai 200433, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2010年 / 17卷 / 12期

关键词：

Protein tyrosine kinases; Src kinases; SH2; SH3; inhibitor; peptidomimetic; nonpeptide; progress; GROWTH-FACTOR RECEPTOR; STRUCTURE-BASED DESIGN; NONPEPTIDE INHIBITORS; TYROSINE KINASE; SMALL-MOLECULE; ACTIVATED SRC; LIGANDS; CELL; BINDING; CANCER;

D O I：

10.2174/092986710790827861

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.

引用

页码：1117 / 1124

页数：8

共 50 条

[21] AN RNA-BINDING PROTEIN ASSOCIATED WITH SRC THROUGH ITS SH2 AND SH3 DOMAINS IN MITOSIS
TAYLOR, SJ
SHALLOWAY, D
NATURE, 1994, 368 (6474) : 867 - 871
[22] Novel Roles of SH2 and SH3 Domains in Lipid Binding
Sipeki, Szabolcs
Koprivanacz, Kitti
Takacs, Tamas
Kurilla, Anita
Laszlo, Loretta
Vas, Virag
Buday, Laszlo
CELLS, 2021, 10 (05)
[23] Structural, dynamic, and folding studies of SH2 and SH3 domains
FormanKay, JD
Pascal, SM
Singer, AU
Yamazaki, T
Zhang, OW
Farrow, NA
Kay, LE
NMR AS A STRUCTURAL TOOL FOR MACROMOLECULES: CURRENT STATUS AND FUTURE DIRECTIONS, 1996, : 35 - 47
[24] A novel SH3 ligand contained within an SH2 domain
Brazin, KN
Fulton, DB
Andreotti, AH
BIOPHYSICAL JOURNAL, 2000, 78 (01) : 150A - 150A
[25] Cooperative interactions between Lck SH2 and SH3 domains
Leavitt, S
Stillman, J
Luque, I
Freire, E
BIOPHYSICAL JOURNAL, 2001, 80 (01) : 560A - 560A
[26] Progress in the development of inhibitors of SH2 domains
Cody, WL
Lin, ZW
Panek, RL
Rose, DW
Rubin, JR
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (01) : 59 - 98
[27] Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation
John C. Morgan
John E. Majors
Deni S. Galileo
Clinical & Experimental Metastasis, 2005, 22 : 167 - 175
[28] THE SOLUTION STRUCTURE OF ABL SH3, AND ITS RELATIONSHIP TO SH2 IN THE SH(32) CONSTRUCT
GOSSER, YQ
ZHENG, J
OVERDUIN, M
MAYER, BJ
COWBURN, D
STRUCTURE, 1995, 3 (10) : 1075 - 1086
[29] NCK, A MELANOMA CDNA-ENCODING A CYTOPLASMIC PROTEIN CONSISTING OF THE SRC HOMOLOGY UNITS SH2 AND SH3
LEHMANN, JM
RIETHMULLER, G
JOHNSON, JP
NUCLEIC ACIDS RESEARCH, 1990, 18 (04) : 1048 - 1048
[30] Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation
Morgan, JC
Majors, JE
Galileo, DS
CLINICAL & EXPERIMENTAL METASTASIS, 2005, 22 (02) : 167 - 175

← 1 2 3 4 5 →